SGMO · Categories · Form 4

SGMO - SEC Form 4 insider transactions

Sangamo Therapeutics Inc. (SGMO) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for SGMO

• 14d
  Principal Accounting Officer Jain Nikunj covered exercise/tax liability with 1,919 shares, decreasing direct ownership by 0.81% to 235,292 units (SEC Form 4) (for withholding tax)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 14d
  Head of Research & Technology Davis Gregory D covered exercise/tax liability with 1,630 shares, decreasing direct ownership by 1% to 113,654 units (SEC Form 4) to cover withholding tax

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 14d
  SVP-CHIEF DEVELOPMENT OFFICER Dubois-Stringfellow Nathalie covered exercise/tax liability with 4,036 shares, decreasing direct ownership by 1% to 328,733 units (SEC Form 4) (for withholding tax)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 14d
  PRESIDENT, CEO AND DIRECTOR Macrae Sandy covered exercise/tax liability with 12,613 shares, decreasing direct ownership by 0.66% to 1,895,043 units (SEC Form 4) (for tax liability)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 14d
  SVP, CHIEF LEGAL OFFICER, SECY Willoughby Scott B. covered exercise/tax liability with 4,036 shares, decreasing direct ownership by 0.62% to 647,370 units (SEC Form 4) (for withholding tax)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 49d
  Head of Research & Technology Davis Gregory D sold $17,694 worth of shares (69,827 units at $0.25), decreasing direct ownership by 38% to 115,284 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 49d
  SVP-CHIEF DEVELOPMENT OFFICER Dubois-Stringfellow Nathalie sold $89,184 worth of shares (345,942 units at $0.26), decreasing direct ownership by 51% to 332,769 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 69d
  SEC Form 4 filed by Macrae Sandy

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 69d
  SEC Form 4 filed by Dubois-Stringfellow Nathalie

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 69d
  SEC Form 4 filed by Jain Nikunj

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 69d
  SEC Form 4 filed by Davis Gregory D

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 69d
  SEC Form 4 filed by Willoughby Scott B.

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 104d
  SVP, CHIEF LEGAL OFFICER, SECY Willoughby Scott B. covered exercise/tax liability with 14,004 shares, decreasing direct ownership by 2% to 651,406 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 104d
  Head of Research & Technology Davis Gregory D covered exercise/tax liability with 5,951 shares, decreasing direct ownership by 3% to 185,111 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 136d
  Principal Accounting Officer Jain Nikunj covered exercise/tax liability with 7,721 shares, decreasing direct ownership by 3% to 242,996 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 136d
  PRINCIPAL FINANCIAL OFFICER Duraibabu Prathyusha covered exercise/tax liability with 36,676 shares, decreasing direct ownership by 5% to 660,042 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 136d
  SVP, CHIEF LEGAL OFFICER, SECY Willoughby Scott B. covered exercise/tax liability with 36,676 shares, decreasing direct ownership by 5% to 665,410 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 136d
  PRESIDENT, CEO AND DIRECTOR Macrae Sandy covered exercise/tax liability with 102,950 shares, decreasing direct ownership by 5% to 1,946,584 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 136d
  Head of Research & Technology Davis Gregory D covered exercise/tax liability with 7,721 shares, decreasing direct ownership by 4% to 191,062 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 136d
  SVP-CHIEF DEVELOPMENT OFFICER Dubois-Stringfellow Nathalie covered exercise/tax liability with 36,676 shares, decreasing direct ownership by 5% to 693,128 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 197d
  Principal Accounting Officer Jain Nikunj covered exercise/tax liability with 578 shares, decreasing direct ownership by 0.23% to 245,717 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 197d
  SVP, CHIEF LEGAL OFFICER, SECY Willoughby Scott B. covered exercise/tax liability with 2,035 shares, decreasing direct ownership by 0.29% to 702,086 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 197d
  PRESIDENT, CEO AND DIRECTOR Macrae Sandy covered exercise/tax liability with 7,488 shares, decreasing direct ownership by 0.36% to 2,049,534 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 197d
  PRINCIPAL FINANCIAL OFFICER Duraibabu Prathyusha covered exercise/tax liability with 2,544 shares, decreasing direct ownership by 0.36% to 696,718 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 197d
  SVP-CHIEF DEVELOPMENT OFFICER Dubois-Stringfellow Nathalie covered exercise/tax liability with 2,544 shares, decreasing direct ownership by 0.35% to 719,804 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 197d
  Head of Research & Technology Davis Gregory D covered exercise/tax liability with 723 shares, decreasing direct ownership by 0.37% to 193,791 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 230d
  SVP-CHIEF DEVELOPMENT OFFICER Dubois-Stringfellow Nathalie covered exercise/tax liability with 43,741 shares, decreasing direct ownership by 6% to 722,348 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 230d
  PRINCIPAL FINANCIAL OFFICER Duraibabu Prathyusha covered exercise/tax liability with 45,225 shares, decreasing direct ownership by 6% to 699,262 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 230d
  SVP, CHIEF LEGAL OFFICER, SECY Willoughby Scott B. covered exercise/tax liability with 44,122 shares, decreasing direct ownership by 6% to 704,121 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 230d
  PRESIDENT, CEO AND DIRECTOR Macrae Sandy covered exercise/tax liability with 126,950 shares, decreasing direct ownership by 6% to 2,057,022 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 230d
  Principal Accounting Officer Jain Nikunj covered exercise/tax liability with 6,708 shares, decreasing direct ownership by 3% to 246,295 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 230d
  Head of Research & Technology Davis Gregory D covered exercise/tax liability with 6,708 shares, decreasing direct ownership by 3% to 194,514 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 288d
  PRESIDENT, CEO AND DIRECTOR Macrae Sandy covered exercise/tax liability with 7,488 shares, decreasing direct ownership by 0.34% to 2,183,972 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 288d
  Head of Research & Technology Davis Gregory D covered exercise/tax liability with 723 shares, decreasing direct ownership by 0.36% to 201,222 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 288d
  SVP, CHIEF LEGAL OFFICER, SECY Willoughby Scott B. covered exercise/tax liability with 1,434 shares, decreasing direct ownership by 0.19% to 748,243 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 288d
  SVP, CHIEF FINANCIAL OFFICER Duraibabu Prathyusha covered exercise/tax liability with 1,792 shares, decreasing direct ownership by 0.24% to 744,487 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 288d
  SVP-CHIEF DEVELOPMENT OFFICER Dubois-Stringfellow Nathalie covered exercise/tax liability with 1,792 shares, decreasing direct ownership by 0.23% to 766,089 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 322d
  SVP, CHIEF FINANCIAL OFFICER Duraibabu Prathyusha covered exercise/tax liability with 31,866 shares, decreasing direct ownership by 4% to 746,279 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 322d
  PRESIDENT, CEO AND DIRECTOR Macrae Sandy covered exercise/tax liability with 126,950 shares, decreasing direct ownership by 5% to 2,191,460 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 322d
  SVP, CHIEF LEGAL OFFICER, SECY Willoughby Scott B. covered exercise/tax liability with 31,866 shares, decreasing direct ownership by 4% to 749,677 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 322d
  SVP-CHIEF DEVELOPMENT OFFICER Dubois-Stringfellow Nathalie covered exercise/tax liability with 31,866 shares, decreasing direct ownership by 4% to 767,881 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 322d
  Head of Research & Technology Davis Gregory D covered exercise/tax liability with 6,708 shares, decreasing direct ownership by 3% to 201,945 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 360d
  Director Parker H Stewart was granted 25,000 shares, increasing direct ownership by 29% to 112,600 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 360d
  Director Smith Karen L. was granted 25,000 shares, increasing direct ownership by 32% to 102,100 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 360d
  Director Carey Robert was granted 25,000 shares, increasing direct ownership by 34% to 99,600 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 360d
  Director Meyers James R was granted 25,000 shares, increasing direct ownership by 34% to 99,600 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 360d
  Director Markels John was granted 25,000 shares, increasing direct ownership by 35% to 96,384 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 360d
  Director Hillan Kenneth J. was granted 25,000 shares, increasing direct ownership by 34% to 99,600 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 360d
  Director Beers Courtney was granted 25,000 shares, increasing direct ownership by 43% to 82,650 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 360d
  Director Horn Margaret A was granted 25,000 shares, increasing direct ownership by 43% to 82,650 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 379d
  PRESIDENT, CEO AND DIRECTOR Macrae Sandy covered exercise/tax liability with 7,488 shares, decreasing direct ownership by 0.32% to 2,318,410 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 379d
  SVP, CHIEF LEGAL OFFICER, SECY Willoughby Scott B. covered exercise/tax liability with 1,433 shares, decreasing direct ownership by 0.18% to 781,543 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 379d
  SVP, CHIEF FINANCIAL OFFICER Duraibabu Prathyusha covered exercise/tax liability with 1,792 shares, decreasing direct ownership by 0.23% to 778,145 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 379d
  SVP-CHIEF DEVELOPMENT OFFICER Dubois-Stringfellow Nathalie covered exercise/tax liability with 1,792 shares, decreasing direct ownership by 0.22% to 799,747 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 379d
  Head of Research & Technology Davis Gregory D covered exercise/tax liability with 723 shares, decreasing direct ownership by 0.35% to 208,653 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 413d
  SVP, GEN. COUNSEL & SECRETARY Willoughby Scott B. covered exercise/tax liability with 31,866 shares, decreasing direct ownership by 4% to 782,976 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 413d
  SVP, CHIEF FINANCIAL OFFICER Duraibabu Prathyusha covered exercise/tax liability with 31,866 shares, decreasing direct ownership by 4% to 779,937 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 413d
  PRESIDENT, CEO AND DIRECTOR Macrae Sandy covered exercise/tax liability with 126,950 shares, decreasing direct ownership by 5% to 2,325,898 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 413d
  SVP-CHIEF DEVELOPMENT OFFICER Dubois-Stringfellow Nathalie covered exercise/tax liability with 31,866 shares, decreasing direct ownership by 4% to 801,539 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
• 413d
  Head of Research & Technology Davis Gregory D covered exercise/tax liability with 6,708 shares, decreasing direct ownership by 3% to 209,376 units (SEC Form 4)

  4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

Other SGMO categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends